Printer Friendly

Cell Pathways' CP461 Markedly Reduced Disease Symptoms in Canine Model of Refractory Inflammatory Bowel Disease.

Business Editors/Health & Medical Writers

BIOWIRE2K

HORSHAM, Pa.--(BW HealthWire)--May 21, 2002

Drug Induces Selective Apoptosis in Activated Macrophages,

Reducing Inflammatory Modulator that Plays Key Role in the Disease

New research reported today at the American Gastroenterology Association meeting suggests that Cell Pathways' (Nasdaq:CLPA) investigational oral drug CP461 may have potential as a treatment for inflammatory bowel disease (IBD) in addition to its previously reported anticancer activity. Seven dogs with a history of chronic and refractory IBD lasting six months to 3.5 years who had failed to respond to conventional therapies were selected for the study. The clinical signs of IBD started to resolve by day 10 after treatment, and 86% of the dogs were free of symptoms by day 30.

In addition, tissue samples surgically obtained from one of the dogs before and after treatment showed marked improvement of the diseased intestinal tract after treatment with CP461. In particular, CP461 reduced the number of activated macrophages and lymphocytes, types of white blood cells involved in inflammation, and the morphology of the intestinal tract had returned to normal after treatment. In studies of diseased canine and human tissues, high levels of cyclic GMP phosphodiesterases (cGMP PDE) of the PDE2 and PDE5 gene families have been detected (both molecular targets for CP461) in activated macrophages associated with IBD. These results are consistent with the demonstration that CP461 has a potent ability to trigger apoptosis (programmed cell death) in activated macrophages, which play a central role in IBD. These cells produce chemical modulators of inflammation -- cytokines such as tissue necrosis factor-alpha (TNF(alpha)) -- that cause intestinal inflammation and damage.

"Canines are naturally subject to IBD that appears to be similar to the disease in humans, making dogs an excellent model for the study of potential new treatments for this condition," said Hector Alila, D.V.M., Ph.D., vice president, product development. "Current treatments for IBD have limited effectiveness and/or toxicity. Studies to date indicate that CP461, an oral drug, is generally well tolerated. Furthermore, it appears to act by targeting cells (activated macrophages) that are the source of harmful cytokines such as TNF(alpha). On the basis of these intriguing preclinical results, we are planning to initiate a human clinical trial of CP461 in inflammatory bowel disease later this year."

CP461 Drug Target Demonstrated

The researchers first showed that human intestinal biopsy samples from patients with confirmed IBD contained tissue-activated macrophages with high levels of PDE2 and PDE5, two cellular targets of CP461 and Cell Pathways' other selective apoptotic antineoplastic drugs (SAANDs). Such macrophages are known to release TNF(alpha), an immune modulator that plays a central role in IBD. The researchers then demonstrated the ability of CP461 to induce apoptosis and inhibit TNF(alpha) in a human macrophage cell line. They found that treatment of the cells with 1(mu)M (micromolar) CP461 (the levels that can be achieved in bloodstream of patients) for 24 hours increased apoptosis rates by 64% in the cells and reduced production of TNF(alpha) by 23%.

"Based on these findings, we hypothesized that using CP461 to selectively induce apoptosis in tissue-activated macrophages might provide a novel approach to the treatment of IBD," said Cell Pathways' scientist, Keith Earle, D.V.M., who presented the research findings.

Canine Study

In collaboration with Linda J.M. Tintle, D.V.M, of the Wurtsboro Veterinary Clinic in Wurtsboro, N.Y., the researchers treated seven companion dogs having a history of IBD refractory to conventional therapies (including steroids, antibiotics and dietary management) with CP461. The dogs received either 400 mg or 800 mg of oral CP461 twice daily for 60 consecutive days, followed by a 30-day recovery period. Within 10 days of starting treatment, all dogs ceased their vomiting, diarrhea and weight loss. By day 30, 86% of the dogs were free of symptoms. There was a recurrence of symptomatic disease following cessation of treatment. Subsequently, four of the dogs were retreated with 400 mg or 800 mg twice daily for 30 days, followed by a maintenance dose of 100 mg or 200 mg twice daily for 30 days. Three of the four dogs responded to therapy and were symptomatically normal throughout the treatment period.

Intestinal biopsies obtained from one dog before treatment showed high levels of PDE2 and PDE5 in the activated macrophages. These macrophages were greatly reduced in biopsies from the same animal and histopathological improvement was obtained after treatment with CP461. Correlative studies performed with archived human intestinal biopsies also showed elevated levels of PDE2 and PDE5 in diseased IBD tissues but not in normal tissues, similar to the findings in the dogs.

About Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a collective term for a group of inflammatory diseases of the gastrointestinal tract. In humans, IBD is generally divided into two major types: ulcerative colitis, which affects only the colon, and Crohn's disease, which can affect any part of the digestive tract. Both diseases are characterized by an abnormal immune response in the gastrointestinal system that causes uncontrolled inflammation. While both diseases share the common symptoms of crampy abdominal pain and diarrhea, other significant differences between the two may include the sites affected, treatment, prognosis and complications. Crohn's disease is associated with excessive infiltration of inflammatory and immune cells that are resistant to apoptosis. These cells produce cytokines such as TNF(alpha), which contribute to chronic intestinal inflammation and tissue damage. Current treatments have limited effectiveness and/or toxicity. Physicians and patients agree there is great need for new agents to treat IBD.

According to National Institutes of Health statistics, the incidence of Crohn's disease in the United States is 7 people per 100,000 and overall, 300,000 to 500,000 people suffer from this disease. Similarly, the NIH states the incidence of ulcerative colitis is 10-15 people out of 100,000.

About CP461

CP461 is a second-generation SAAND, a class of orally active compounds discovered and under development by Cell Pathways, Inc. SAANDs selectively trigger apoptosis in abnormal cells by inhibiting certain cGMP PDE that company scientists and collaborators have shown to be over-expressed in a variety of tumor types and in activated macrophages associated with IBD. This cGMP PDE inhibition leads to activation of another intracellular signaling molecule, protein kinase G, triggering a cascade of downstream events leading to apoptosis. Cell Pathways is currently conducting Phase IIa clinical trials of CP461 in a variety of cancers including chronic lymphocytic leukemia, hormone-refractory prostate cancer, and advanced kidney cancer.

About Cell Pathways

Cell Pathways, Inc., headquartered in Horsham, Pa., is a development stage pharmaceutical company focused on the research and development of novel and unique medications to treat and prevent cancer and to treat certain inflammatory diseases. The company additionally markets and sells oncology-related products made by others. The company's initial drug candidates in clinical development are Aptosyn(R) (exisulind) and CP461. For additional information on Cell Pathways, Inc., visit the Company's web site at http://www.cellpathways.com.

Certain statements made herein, and oral statements made in respect hereof, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are those, which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such risks and uncertainties relate to, among other factors: early stage of development; the costs, delays and uncertainties inherent in scientific research, basic pharmaceutical research, drug development, clinical trials and the regulatory approval process, with respect to both our current product candidates and our future product candidates, if any; limitations on, or absence of, the predictive value of data obtained in laboratory tests, animal models and human clinical trials when planning additional steps in product development; uncertainty that additional studies, if any, may not be positive; uncertainty of obtaining regulatory approval of any compound for any disease indication whether due to adequacy of the development program, changing regulatory requirements or otherwise; the absence of approved products; history of operating losses and the need for further financing; dependence on the development, regulatory approval and market acceptance of one or more of our product candidates for one or more significant disease indications; the risk that the Company does not conduct the clinical studies it may have planned to conduct or does not pursue development plans it may have planned to pursue; the risk that clinical studies do not result in the safety and efficacy necessary to obtain regulatory approvals; the risks of conducting clinical trials, including the risk of conducting clinical trials of our drugs in combination with other drug therapies; the commercial risk and risk of liability in marketing and selling Gelclair(TM) Concentrated Oral Gel; and providing marketing services promoting Nilandron(R) (nilutamide) manufactured by Aventis Pharmaceuticals, Inc.; the risk that the Company may enter into, or may fail to enter into, licensing, partnership or collaborative arrangements or strategic alliances which accord to other companies rights with respect to one or more Company compounds, technologies or programs or in which the Company acquires new rights and obligations; the volatility of the market price of our Common Stock; our ability to sell securities registered under the shelf registration statement; acceptance of any product candidates by physicians and providers of healthcare reimbursement; the actions of competitors; the pace of technological changes in the biopharmaceutical industry; dependence upon third parties; the validity, scope and enforceability of patents; the risk of pending or future class action securities litigation; potential product liability claims; and availability and adequacy of insurance. These and other risks are detailed in our reports filed from time to time under the Securities Act and/or the Securities Exchange Act, including the sections entitled "Business," "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Other Events" in our annual reports on Form 10-K, quarterly reports on Form 10-Q and periodic reports on Form 8-K and in such registration statements on Form S-3 as we may file from time to time. You are encouraged to read these filings as they are made. They are available over the Internet from the SEC in its EDGAR database at http://www.sec.gov and from the Company. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. No forward-looking statement can be guaranteed; actual future results may vary materially. Both forward-looking statements and statements of historic fact must be understood in the context of the risks referred to above which characterize our development stage business. We undertake no obligation to update or revise the statements made herein or the risk factors that may relate thereto.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Cell Pathways' CP461 Markedly Reduced Disease Symptoms in Canine Model of Refractory Inflammatory Bowel Disease.
Publication:Business Wire
Geographic Code:1USA
Date:May 21, 2002
Words:1824
Previous Article:Symantec Announces New Firewall and VPN Appliance Offering Enhanced Speed and Integrated High Availability/Load Balancing.
Next Article:Cypress Delivers Next-Generation USB 2.0 Mass Storage Bridge Solution.
Topics:


Related Articles
Nasal septal perforation: A rare extraintestinal manifestation of Crohn's disease.
AMT GETS EUR 1.8 MILLION FOR EX VIVO GENE THERAPY FOR CROHN'S.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters